Bradyarrhythmia is a common clinical manifestation. Although the majority of cases are acquired, genetic analysis of families with bradyarrhythmia has identified a growing number of causative gene mutations. Because the only ultimate treatment for symptomatic bradyarrhythmia has been invasive surgical implantation of a pacemaker, the discovery of novel therapeutic molecular targets is necessary to improve prognosis and quality of life.
S
inus node cells, located in the right atrium, spontaneously produce an electric impulse (ie, action potential) that propagates along the cardiac conduction system and causes contraction of the heart muscle. 1 Thus, heart rate is precisely regulated within the proper range by both intrinsic and extrinsic mechanisms. Intrinsic heart rate is determined by the automatic pacemaker activity of the sinus node. 2 Extrinsic regulation in response to physical and mental activity is achieved by the opposing actions of sympathetic (β-adrenergic) and parasympathetic (muscarinic or vagal) stimulation. 3 The acetylcholine-activated potassium channel (I KACh channel) expressed in the sinus node, atrium, and atrioventricular node 4, 5 contributes to heart rate slowing triggered by the parasympathetic nervous system. 6, 7 The I KACh channel is a heterotetramer of 2 inwardly rectifying potassium channel proteins, Kir3.1 and Kir3.4, encoded by the genes KCNJ3 and KCNJ5, respectively. 4 The genetic basis of I KACh in heart rate regulation could not be identified by either candidate gene resequencing of KCNJ3 and KCNJ5 in individual patients with sinus node dysfunction or meta-analysis of genome-wide association studies. 8, 9 Of note are some reports indicating relationships between KCNJ5 and atrial fibrillation (AF). 10, 11 However, the molecular basis of I KACh channel pathology remains poorly understood and, to date, rare mutations showing a large effect have not been reported for cardiac diseases.
In this study, we identified a novel nonsynonymous mutation in KCNJ3 in a family affected by hereditary bradyarrhythmias and elucidated the pathophysiological role of the I KACh channel. Using an animal model, we investigated the possibility of the I KACh channel becoming a pharmacological target in human cardiac diseases.
METHODS

Data Disclosure Statement
The data that support the findings of this study are available from the corresponding author on reasonable request. Extended methods and associated references are given in the online-only Data Supplement.
Study Approval
This study was performed under the ethical code approved by the Ministry of Health, Labor and Welfare of Japan, and written informed consent was obtained from all subjects or their guardians before inclusion in the study. The genome research protocol was approved by the Human Genome Research Bioethical Committee at Osaka University, Kyoto University, Shiga University of Medical Science, Tokyo Medical and Dental University, Saitama Red Cross Hospital, Tsuchiura Kyodo Hospital, and National Disaster Medical Hospital. All procedures of Xenopus laevis oocytes and zebrafish studies were performed in conformity with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication No. 85-23, revised 1996) and were approved by the Osaka University Committee for Laboratory Animal Use.
Study Subjects and Genetic Analysis
A family affected by hereditary bradyarrhythmia (diagnosed at Osaka University Hospital) was enrolled. Whole exome sequencing was performed on 4 affected family members (II:5, II:7, III:2, and III:4) and one clinically nonaffected individual (II:3). Filtering of detected variants to be considered as candidates for analysis was performed by applying the following inclusion criteria (Table I in the online-only Data Supplement): (1) heterozygous variants; (2) exonic variants; (3) variants other than synonymous ones; and (4) variants absent from dbSNP135 12 and variants with a minor allele frequency <0.1% in multiple variation databases (in the online-only Data Supplement Methods). Linkage analysis was performed for 13 affected and nonaffected family members in 2 steps by using single-nucleotide polymorphisms and polymorphic microsatellite markers. Target resequencing of the KCNJ3 and KCNJ5 genes was performed using pooled DNA samples (ie, Pool-Seq) in a cohort of 2185 individuals with AF. The outpatients and inpatients aged ≥20 were recruited from the cardiology departments of the 4 hospitals of Tokyo Medical and
Clinical Perspective
What Is New?
• We identified KCNJ3 as a novel causative gene for hereditary bradyarrhythmias.
• The mutation caused a gain of acetylcholine-activated potassium channel (I KACh channel) function by increasing the basal current and open probability, even in the absence of m 2 muscarinic receptor stimulation.
• A selective I KACh channel blocker effectively inhibited the mutant I KACh channel and upregulated heart rate in bradyarrhythmias using a zebrafish model. • We also identified 5 rare mutations in the KCNJ3
and KCNJ5 genes from a cohort of 2185 individuals with sporadic atrial fibrillation.
What Are the Clinical Implications?
• Pharmacological blockade of I KACh channels should be a safe therapy for increasing heart rate and should be especially beneficial for patients who have bradyarrhythmia with gain-of-function mutations in the I KACh channel.
• In clinical settings, although there may be patients with bradyarrhythmias associated with functional mutations in the I KACh channel, the prevalence of such patients remains to be elucidated by further studies with larger cohorts.
• Genetic testing for KCNJ3 and KCNJ5 in patients with bradyarrhythmias may provide a drug treatment option in lieu of invasive surgical implantation of a pacemaker.
Patch-Clamp Analysis
The Kir3.1 and Kir3.4 subcloned into pcDNA3 (Invitrogen) were transfected into HEK293T cells using the Lipofectamine Plus reagent (Invitrogen). Single-channel activity was recorded in a cell-attached configuration at a holding potential of -100 mV using a patch-clamp amplifier (Axopatch 200B; Axon Instruments). Inside-out patch-clamp experiments were performed by excision of patch membranes in the cell-attached configuration. To reveal the maximal channel activity in the patch membrane, ATP (2 mmol/L) and GTPγS (10 μmol/L) were perfused at the intracellular side of membranes to generate phosphatidylinositol 4,5-bisphosphate and Gβγ free from the Gα subunit, respectively.
Zebrafish Experiments
General maintenance, collection, and staging of the zebrafish were performed according to established conventions. 16 We used 2 zebrafish lines, Casper 17 and hspGFF3A. 18 The expression plasmid (pT2AUASMCS), containing 3 genes, human KCNJ3 (Kir3.1-WT or -N83H), human KCNJ5, and mCherry, driven by the atrial myosin heavy chain (amhc) promoter, was produced by inserting genes using unique restriction sites between two 2A peptides (P2A and T2A). In vitro synthesis of the Tol2 transposase mRNA was performed as described previously. 19 The transposase mRNA was coinjected with the transgene into fertilized eggs of Casper line zebrafish at the 1-cell stage. The mCherry-positive F0 fish were raised to adulthood and crossed with hspGFF3A line zebrafish, which express green fluorescent protein in both the atrium and the ventricle. F1 transgenic fish with green fluorescent protein both in the atrium and the ventricle and with mCherry in the atrium were selected for phenotype evaluation and pharmacological analysis of NIP-151.
Statistical Analysis
Data are represented as mean±SEM Mann-Whitney U test was used for comparisons between 2 groups. One-way or 2-way ANOVA was used for comparisons among ≥3 groups. Selected analytical methods are described in the figure legends. Differences were considered significant if a P value was <0.05. In all figures, an asterisk (*) indicates P<0.05, and 2 asterisks (**) indicate P<0.01.
RESULTS
KCNJ3 Mutation in a Family With Autosomal Dominant Bradyarrhythmias
We performed genetic analysis for large Asian families with sinus node dysfunction and AF to identify novel potentially pathogenic mutations. Herein, we report on a Japanese family affected by hereditary bradyarrhythmias showing an autosomal dominant inheritance pattern ( Figure 1A and Table) . Four individuals exhibited symptomatic sinus bradycardia, and 2 exhibited chronic AF with slow ventricular response ( Figure 1B ). In addition, 2 individuals were affected by sinus bradycardia, one subsequently developed paroxysmal atrioventricular block, and the other developed AF at a young age. To identify the causative mutation, we conducted family-based whole exome sequencing of 5 family members (4 affected and 1 unaffected) and detected ≈200 000 variants in each individual ( Figure I in the online-only Data Supplement), where only 2 variants were included. After assessing the potential effect of the variants on protein function by PolyPhen-2 20 and the Combined Annotation-Dependent Depletion Phred score, 21 only one variant, KCNJ3 c.247A>C on chromosome 2, was predicted to be disease causing (PolyPhen-2 score: 0.995; Combined Annotation-Dependent Depletion Phred score: 19.1). KCNJ3 c.247A>C has not been previously reported in any database of genetic variations. Moreover, no pathological mutation in KCNJ3 has been reported to be associated with human disease in the past. We verified this mutation by Sanger sequencing and restriction fragment length polymorphism analysis, which showed the complete segregation of this mutation with the affected phenotype ( Figure 1C and Figure II in the online-only Data Supplement). Thus, the heterozygous mutation in KCNJ3 (NM_001260508: c.247A>C, p.N83H) seems to be a novel cause of hereditary bradyarrhythmias in this family. 
Target Resequencing of KCNJ3 and KCNJ5 in Genomic Samples From a Patient Cohort
We hypothesized that not only KCNJ3 c.247A>C, p.N83H identified in the family, but also many other genetic mutations in the I KACh channel subunit genes (ie, KCNJ3 and KCNJ5) could predispose to sinus node dysfunction and AF. Therefore, we screened the coding and exon flanking regions of the KCNJ3 and KCNJ5 genes from 2185 unrelated subjects with AF (Table III in the online-only Data Supplement), first by analysis of target resequencing of pooled DNA samples (ie, Pool-Seq; Table IV in the online-only Data Supplement), and then by individual Sanger sequencing. After focusing on missense, splice-site, stop-gain or stop-loss, and frameshift variants with a minor allele frequency <0.1% in gnomAD 22 and confirming them by Sanger sequencing, in addition, we identified 5 rare heterozygous mutations in KCNJ3 and KCNJ5 genes (KCNJ3 c.253T>C, p.F85L, KCNJ3 c.1486A>C, p.N496H, KCNJ5 NM_000890: c.785A>G, p.D262G, KCNJ5 c.907G>A, p.V303I, and KCNJ5 c.1159G>A, p.G387R) in a total of 19 patients ( Figure 1D , Figure III in the online-only Data Supplement, and Tables V and VI in the onlineonly Data Supplement). KCNJ3 N83 and KCNJ5 V303 are highly conserved among both orthologues and Kir3 channel family members, whereas the other 4 residues are conserved among orthologues only ( Figure 1D ). This is the first report of 3 of the 5 rare mutations, KCNJ3 c.253T>C, p.F85L, KCNJ5 c.785A>G, p.D262G, and KCNJ5 c.907G>A, p.V303I, harbored by individual subjects. KCNJ5 p.D262G and KCNJ5 p.V303I were predicted to be disease causing (Polyphen-2 score: 0.622; Combined Annotation-Dependent Depletion Phred score: 23.6; Polyphen-2 score: 1.000; Combined Annotation-Dependent Depletion Phred score: 24.1, respectively; Table V in the online-only Data Supplement). The other 2 mutations (ie, KCNJ3 c.1486A>C, p.N496H and KCNJ5 c.1159G>A, p.G387R), found in 10 and 6 subjects in our AF patient cohort, respectively (n=2185; Table VI in the online-only Data Supplement), are rare variants (rs766625367 and rs199830292, respectively). We used variant frequency data for 3552 Japanese individuals in the general population (the integrative Japanese Genome Variation Database: iJGVD 3.5KJPN) 23 to compare the allele frequency of each variant (Table V in the online-only Data Supplement). With regard to KCNJ3 c.1486A>C, p.N496H, the allele frequency in our AF patient cohort was significantly higher than that of iJGVD 3.5KJPN (10/4370 versus 4/7106; Fisher exact test, P=0.013; odds ratio, 4.072). Thus, there is a possibility that the KCNJ3 p.N496H mutation is associated with an increased risk of developing AF. As for KCNJ5 c.1159G>A, p.G387R, the allele frequency in our AF patient cohort was comparable with that of iJGVD 3.5KJPN (6/4370 versus 12/7086; Fisher exact test, P=0.810), suggesting that this variant is likely to be benign or to exert only mild effects.
Furthermore, we checked for these variants in another cohort of 1094 general Japanese men 24 and found the KCNJ3 c.1486A>C variant in 2 individuals (Table VII in the online-only Data Supplement). It is interesting to note that they were revealed to have AF and sinus bradycardia, respectively, after precise clinical information screening. The individual with AF showed ventricular pauses on 24-hour Holter electrocardiography monitoring ( Figure IV in the online-only Data Supplement). These findings of novel and rare mutations identified in the KCNJ3 and KCNJ5 genes supported our hypothesis and motivated us to clarify the pathogenic roles of these variants in bradyarrhythmias and AF.
Electrophysiological Analysis of the KCNJ3 and KCNJ5 Mutants
According to the crystal structure of various Kir channels, it could be postulated that Kir3 possesses cytoplasmic N and C termini flanked by a transmembrane domain. 25 The transmembrane domain is composed of 2 transmembrane (M1 and M2) helices and a pore helix with an ion selectivity filter. 26, 27 Structural prediction indicated that residues N83 and F85 of Kir3.1 (KCNJ3) would be located on the cytoplasmic side of helix M1, in close proximity to both the M2 and slide helices. Residues N496 of Kir3.1 and D262, V303, and G387 of Kir3.4 (KCNJ5) are located in the intracellular C termini and luminal side of the complex ( Figure 1E ).
Among these variants, we focused on the Kir3.1-N83H mutation identified in the family with complete penetrance and performed functional analysis. I KACh channels are activated by vagal neurotransmitter acetylcholine (ACh) binding to m 2 R. 28 To elucidate the electrophysiological properties and the causal relationship between the Kir3.1 mutation and the disease phenotype, membrane currents of Xenopus oocytes expressing Kir3.1-WT or Kir3.1-mutant (N83H) along with Kir3.4 and m 2 R were recorded using twoelectrode voltage clamp. The Kir3.1-WT channels induced a small basal current and a large K + current on administration of ACh. Kir3.1-N83H also induced an ACh-dependent K + current; however, in comparison 
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with the steady-state K + current in the presence of ACh, the basal activity of the mutant in the absence of stimulation was about twice as large as that of Kir3.1-WT (Figure 2A) . The heterologous Kir3.1-WT/N83H channels exhibited basal activity intermediate between those of the pure Kir3.1-WT and Kir3.1-N83H channels. The absolute current values of the Kir3.1-N83H and Kir3.1-WT/N83H channels at -100 mV and +20 mV were significantly larger than that of Kir3.1-WT both at baseline and after ACh stimulation ( Figure To assess the response of the channel activity to G-protein stimulation, we measured the K + currents in various concentrations of ACh. All channels were activated by ACh administration in a concentrationdependent manner ( Figure VD in the online-only Data Supplement). The half-maximal effective concentration (EC 50 ) values of the Kir3.1-N83H and Kir3.1-WT/ N83H channels were comparable to those of the Kir3.1-WT channel. Thus, the mutation increases the basal channel activity in the absence of G-protein stimulation, but does not perturb G-protein sensitivity. The increase in the channel activity caused by the Kir3.1 mutation was also observed in a previous in vitro study on Kir3.2 (KCNJ6) with the same mutation at the identical position of N83 of Kir3.1 (Kir3.2-N94H), 29 highlighting the crucial role of this position in the channel properties.
With regard to another 5 rare mutations of KCNJ3 and KCNJ5 identified from a patient cohort of AF, we compared the currents measured from oocytes injected with equimolar amounts of the cRNAs of KCNJ3 and KCNJ5 for each mutation ( Figure 
Patch-Clamp Analysis of the Kir3.1-N83H Mutant Channel
To reveal the mechanism underlying the increase in basal current amplitude of channels carrying the N83H mutation, we measured single-channel currents from HEK293T cells ( Figure 2B and Figure VII in the online-only Data Supplement). Two different patch configurations of the patched membrane were used for the recording: cell-attached patch and inside-out patch. The Kir3.1-WT/Kir3.4 channels exhibited rare and spiky channel openings in the cell-attached patch configuration, whereas, in the same patched membrane, there were a significant number of channels that could be activated by G-protein stimulation. By contrast, the Kir3.1-N83H/Kir3.4 channels exhibited CAP; top) . After the recording, the patches were excised to form the inside-out patch configuration (I/O; bottom). To reveal the maximal channel activity in the patch membrane, ATP (2 mmol/L) and GTPγS (10 μmol/L) were perfused at the intracellular side of membranes to generate PIP 2 and Gβγ free from Gα subunit, respectively. The arrow to the left of the trace represents the zero current level. C, Inward rectification property of Kir3.1-WT, Kir3.1-N83H, and Kir3.1-WT/N83H channels. The channels were coexpressed in Xenopus oocytes along with Kir3.4, Gβ1, and Gγ2. K + currents were recorded with ramp voltage pulses from -140 mV to +50 mV for 2 s from the holding potential of -20 mV. The pulses were administered every 5 s. The Ba 2+ -sensitive currents normalized to that recorded at -70 mV are shown. Data points represent mean±SEM. At voltages above E K (-10 mV, +10 mV, +30 mV, and +50 mV), the current amplitudes of Kir3.1-N83H and Kir3.1-WT/N83H channels were significantly larger than that of the Kir3.1-WT channel (n=7 for Kir3.1-WT; n=5 for Kir3.1-N83H; n=6 for Kir3.1-WT/N83H). **P<0.01 by 2-way ANOVA with the Scheffé post hoc test. The absolute values of currents before normalizing are shown in Figure IXB 
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bursts of openings even in the absence of stimulation. G-protein stimulation of the Kir3.1-N83H/Kir3.4 channels led to augmentation of both bursting and single-spiky channel openings despite there being fewer channels than in the Kir3.1-WT/Kir3.4 channels ( Figure 2B and Figure Figure VIIID in the onlineonly Data Supplement). We observed a significant increase in the number of channels multiplied by single-channel open probability after G-protein stimulation in the Kir3.1-WT channels, suggesting that there were many channels in the patched membrane. By contrast, the Kir3.1-N83H channels exhibited a higher number of channels multiplied by single-channel open probability in the absence of stimulation despite there being fewer channels than in the Kir3.1-WT channels, indicating that the Kir3.1-N83H channels were activated, exhibiting bursts of openings even in the absence of stimulation. Thus, the prolonged single-channel open time and higher channel open probability seem to be the key characteristics of the Kir3.1-N83H/Kir3.4 channel that contribute to an increase in the basal current amplitude even in the absence of G-protein stimulation. In addition, for the current-voltage curve, the Kir3.1-N83H/Kir3.4 mutant exhibited a significantly larger outward current than the Kir3.1-WT ( Figure 2C and Figure IXA and IXB in the online-only Data Supplement). The outward component of I KACh is essential for parasympathetic control of heart rate in pacemaker cells. 30, 31 Thus, in addition to the increased basal current, the weakened inward rectification of the Kir3.1-N83H/Kir3.4 mutant appears to be associated with the pathophysiology of bradycardia in this family ( Figure XA and XB in the online-only Data Supplement).
Current Blockage of Reconstituted I KACh Channel by NIP-151
We hypothesized that a selective I KACh channel blocker could ameliorate the clinical phenotypes in this family. We have previously reported that NIP-151, a benzopyran derivative, blocks the I KACh channel expressed in HEK 293 cells at concentrations in the nanomolar range and with a >1000-fold higher selectivity than it has for I Kr . 15 We tested the ability of NIP-151 to block the mutant channels. At all membrane potentials, NIP-151 attenuated the current amplitude of the WT channel ( Figure 3A and Figure XI in the online-only Data Supplement). The current blockage was more effective at potentials above the equilibrium potential of K + (E K ) than at those below E K ( Figure 3B ). Channels containing the N83H mutant were also sensitive to NIP-151 and voltage-dependent, similar to the WT ( Figure 3A and 3B and Figure XI in the online-only Data Supplement). Considering the physiological relevance of the outward component of I KACh , we evaluated the effects of different concentrations of NIP-151 on reconstituted I KACh activity at +40 mV above E K ( Figure 3C ). NIP-151 blocked the Kir3.1-WT channel in a concentration-dependent manner, with a half-maximal inhibitory concentration (IC 50 ) of 230±60 nmol/L (Hill coefficient=0.41±0.03, n=13). The inhibition curves for channels containing the N83H mutant shifted slightly leftward, with an IC 50 of 50±12 nmol/L (Hill coefficient=0.69±0.09, n=14) for the homozygous Kir3.1-N83H channel and an IC 50 of 41±6 nmol/L (Hill coefficient=0.70±0.03, n=12) for the heterozygous Kir3.1-WT/N83H channel ( Figure 3C ). The sensitivity of the Kir3.1-WT and N83H mutant channels to NIP-151 suggests its potential as a therapeutic application in patients harboring the N83H mutation.
Generation of Transgenic Zebrafish Harboring the KCNJ3 Mutation and Pharmacological Analysis of NIP-151
To confirm that the Kir3.1 gain-of-function mutation results in bradycardia in vivo, we generated transgenic zebrafish with the hspGFF3A (expressing green fluorescent protein specifically in the heart) genetic background, 18 which expressed either human Kir3.1-WT or Kir3.1-N83H along with Kir3.4 and mCherry under the regulation of the amhc promoter 32 ( Figure XIIA and XIIB in the online-only Data Supplement). The expressions of mCherry in the Kir3.1-WT and Kir3.1-N83H transgenic zebrafish lines were similar and were restricted to the atrium ( Figure 4A and Figure Because the initial pulse is generated in the sinus node area (defined as a portion of the sinus venosus), we measured sinus rate by motion mode (M-mode) imaging analysis ( Figure These results imply that NIP-151 has the potential to block the mutant I KACh channel in vivo and thereby upregulate heart rate and reverse the effects of the vari- 
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ous detrimental phenotypes of sinus nodal and atrial bradyarrhythmias ( Figure XC in the online-only Data Supplement).
DISCUSSION
Herein, we have reported on one missense mutation in KCNJ3 (c.247A>C, p.N83H) segregating with bradyarrhythmias, with the functional analysis revealing a gainof-function of the I KACh channel. Heart rate is precisely regulated by the opposing influences of sympathetic (β-adrenergic) and parasympathetic (muscarinic or vagal) stimulation. β-Adrenergic stimulation causes a positive chronotropic effect attributable to hyperpolarizationactivated inward current (I f ) and inward Ca 2+ current (I Ca ) enhancement. 33, 34 In contrast, I KACh activation by parasympathetic stimulation is involved in the negative chronotropic effect of the parasympathetic nervous system on heart rate. 31, 35 Our study suggests the genetic involvement of the negative chronotropic modulatory I KACh channel in determining the intrinsic heart rate of individuals. To increase heart rate, β-adrenergic agonists and competitive antagonists of m 2 R are available but have adverse effects on cardiovascular diseases, such as positive inotropic action. Pacemaker implantation could be used as a standard treatment for bradyarrhythmias; however, such devices require invasive surgical procedures and are also associated with several potential complications. 36 In the present study using a zebrafish model, we demonstrated that NIP-151 could be applied to upregulate heart rate in bradyarrhythmias caused by a gain-of-function mutation in the I KACh channel. In WT zebrafish, NIP-151 modestly increased the heart rate (10%-20%). It is important to note that, because even the complete attenuation of I KACh channel activity by the gene knockout did not induce deleterious tachycardia, 6 ,37,38 pharmacological blockade of I KACh channels should be a safe therapy for increasing heart rate regardless of whether or not mutations are present.
In the present study, three of the affected individuals harboring KCNJ3 p.N83H presented with permanent or paroxysmal AF. Activation of I KACh on vagal stimulation not only decreases the automaticity of pacemaker cells by hyperpolarizing the resting membrane potential, 7, 39 but also shortens the action potential duration in atrial cells, 39 thereby contributing to the occurrence and maintenance of AF. In fact, in knockout mice lacking the I KACh channel, parasympathetic stimulation does not induce AF. 40 Moreover, a constitutively active form of the I KACh channel is prominent in cardiomyocytes of patients with chronic AF. 41 Therefore, the coexistence of AF in the pedigree members is plausible. From a patient cohort of AF, we identified an additional 5 mutations in the KCNJ3 and KCNJ5 genes. In a functional analysis with Xenopus oocytes, KCNJ3 p.N496H and KCNJ5 p.D262G mutant channels exhibited increased current levels in comparison with the WT channel, although they were not as large as that for KCNJ3 p.N83H. The possible reason for the smaller extent of increased currents of these 2 mutants is that the clinical phenotype of the patients harboring these mutations is not that of significant bradycardia but of AF. It has also been reported that heterogeneity in repolarization may promote AF. 42, 43 Thus, we hypothesize that the KCNJ3 p.N496H and KCNJ5 p.D262G mutants may produce atrial repolarization heterogeneity to cause AF development in affected patients. With regard to the other 3 mutations (KCNJ3 p.F85L, KCNJ5 p.V303I, and KCNJ5 p.G387R), we could not demonstrate functional significance or pathophysiological relevance to AF with the data from our present analyses. Not all mutations in the I KACh channel can cause bradyarrhythmias or AF, and it is possible that loss-of-function mutations such as KCNJ5 p.G247R might also be associated with an increased risk of AF occurrence. 10 Because I KACh channels are expressed more abundantly in the atrium than in the ventricle, 5 the blockage of I KACh is a promising target for atrial-selective AF therapy with a lower risk of ventricular arrhythmia. 44 In fact, NIP-151 converted AF to sinus rhythm in canine models of AF, with significant prolongation of the atrial-specific effective refractory period and without inducing ventricular arrhythmias. 15 These findings underline the importance of the I KACh channel in the pathophysiology of AF and support the idea that the I KACh channel is a suitable pharmacological target for inhibition, enabling treatment of AF and bradycardia, as well. We consider patients harboring gain-of-function mutations in the I KACh channel as suitable candidates for a selective I KACh channel blocker, and detailed in vitro and in vivo functional analyses are required for each mutation to determine the clinical applications of this agent in patients with the mutation.
In conclusion, our study highlights the importance of genetic testing for KCNJ3 and KCNJ5 in patients with hereditary bradyarrhythmia and AF and suggests the possibility of the clinical development of selective I KACh channel blockers.
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